Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Genetic Diagnostics Department, |
RCV001727513 | SCV001976456 | pathogenic | Hereditary factor IX deficiency disease | 2016-01-11 | criteria provided, single submitter | clinical testing | Viafet Genomics Laboratory has identified this variant in a female proband whose male offspring is presenting with Hemophilia B. This variant has been identified in several patients affected with Hemophilia B (PMIDs: 22639855 and 32875744). |
OMIM | RCV000011337 | SCV000031568 | pathogenic | Hemophilia b(m) | 1993-07-01 | no assertion criteria provided | literature only | |
Prevention |
RCV004752695 | SCV005345728 | pathogenic | F9-related disorder | 2024-03-27 | no assertion criteria provided | clinical testing | The F9 c.677G>A variant is predicted to result in the amino acid substitution p.Arg226Gln. This variant, and other substitutions of amino acid residue p.Arg226, including p.Arg226Gly, p.Arg226Trp, p.Arg226Pro, and p.Arg226Leu, have been reported in many patients with mostly severe hemophilia B (see the Factor IX Gene (F9) Variant Database, http://www.factorix.org/; Hamasaki-Katagiri et al. 2012. PubMed ID: 22639855; Giannelli et al. 1994. PubMed ID: 7937052; Huang et al. 2020. PubMed ID: 32875744). This variant has not been reported in a large population database (http://gnomad.broadinstitute.org), indicating this variant is rare. This variant is interpreted as pathogenic. |